Compare Stocks: MIRM, EXEL, ASND, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$227.50 +0.2%	$245.52	$186.05 ▼ $282.15	$14.19B	0.38	702,522 shs	109,289 shs
EXEL Exelixis	$62.81 +3.0%	$56.52	$33.76 ▼ $63.31	$15.54B	0.47	2.60 million shs	1.07 million shs
HALO Halozyme Therapeutics	$121.49 +4.0%	$107.97	$61.22 ▼ $122.33	$13.82B	0.88	1.94 million shs	954,736 shs
MIRM Mirum Pharmaceuticals	$82.59 +3.3%	$93.70	$63.23 ▼ $130.00	$5.36B	0.61	853,252 shs	212,439 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.70%	-0.62%	-14.31%	-12.63%	+8.76%
EXEL Exelixis	+2.49%	+4.36%	+8.50%	+9.54%	+54.37%
HALO Halozyme Therapeutics	+6.57%	+5.44%	+8.23%	+50.66%	+75.27%
MIRM Mirum Pharmaceuticals	+0.43%	-0.84%	-17.35%	-31.87%	+9.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$227.50 +0.2%	$245.52	$186.05 ▼ $282.15	$14.19B	0.38	702,522 shs	109,289 shs
EXEL Exelixis	$62.81 +3.0%	$56.52	$33.76 ▼ $63.31	$15.54B	0.47	2.60 million shs	1.07 million shs
HALO Halozyme Therapeutics	$121.49 +4.0%	$107.97	$61.22 ▼ $122.33	$13.82B	0.88	1.94 million shs	954,736 shs
MIRM Mirum Pharmaceuticals	$82.59 +3.3%	$93.70	$63.23 ▼ $130.00	$5.36B	0.61	853,252 shs	212,439 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.70%	-0.62%	-14.31%	-12.63%	+8.76%
EXEL Exelixis	+2.49%	+4.36%	+8.50%	+9.54%	+54.37%
HALO Halozyme Therapeutics	+6.57%	+5.44%	+8.23%	+50.66%	+75.27%
MIRM Mirum Pharmaceuticals	+0.43%	-0.84%	-17.35%	-31.87%	+9.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$309.26	35.56% Upside
EXEL Exelixis	2.35	Hold	$50.79	-19.52% Downside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$96.50	-20.86% Downside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$147.88	79.44% Upside

Current Analyst Ratings Breakdown

Latest MIRM, EXEL, ASND, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$269.00
10/14/2026	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$136.00 ➝ $156.00
10/13/2026	ASND Ascendis Pharma A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C)
10/13/2026	MIRM Mirum Pharmaceuticals	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$146.00
10/13/2026	HALO Halozyme Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/13/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/12/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$137.00 ➝ $152.00
10/12/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$160.00 ➝ $184.00
10/12/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$195.00 ➝ $200.00
10/9/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$45.00 ➝ $51.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	17.47	N/A	N/A	($2.97) per share	-76.82
EXEL Exelixis	$2.44B	6.42	$3.21 per share	19.66	$8.06 per share	7.83
HALO Halozyme Therapeutics	$1.40B	9.91	$5.31 per share	22.98	$0.42 per share	290.33
MIRM Mirum Pharmaceuticals	$618.07M	8.66	$0.05 per share	1,561.82	$6.12 per share	13.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	17.71	25.49	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	19.83	17.01	1.67	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	36.34	12.46	0.41	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)

Latest MIRM, EXEL, ASND, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ASND Ascendis Pharma A/S	$0.9360	N/A	N/A	N/A	$411.20 million	N/A
11/3/2026	Q3 2026	EXEL Exelixis	$0.8790	N/A	N/A	N/A	$646.95 million	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.4889	N/A	N/A	N/A	$178.06 million	N/A
11/2/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	N/A	N/A	N/A	$487.13 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
HALO Halozyme Therapeutics	13.50	2.71	2.31
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
HALO Halozyme Therapeutics	97.79%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
HALO Halozyme Therapeutics	2.50%
MIRM Mirum Pharmaceuticals	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable

MIRM, EXEL, ASND, and HALO Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP)

October 15 at 7:29 AM | theglobeandmail.com

MIRM Stock Gets Reduced EPS Estimate from HC Wainwright

October 14 at 6:41 AM | marketbeat.com

Citigroup Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

October 14 at 1:36 AM | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 6.4% - Here's What Happened

October 13 at 3:39 PM | marketbeat.com

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

October 13 at 11:45 AM | zacks.com

Q3 EPS Forecast for Mirum Pharmaceuticals Reduced by Analyst

October 13 at 8:26 AM | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Gets Price Target Increase from Citigroup

October 12 at 5:17 PM | marketbeat.com

Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study

October 12 at 3:01 PM | rttnews.com

Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027

October 12 at 3:01 PM | rttnews.com

Mirum Pharmaceuticals Says Livmarli Meets Primary Endpoint in Phase 3 Liver Disease Trial

October 12 at 3:01 PM | finance.yahoo.com

HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

October 12 at 1:17 PM | marketbeat.com

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

October 12 at 1:00 PM | seekingalpha.com

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

October 12 at 11:01 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow

October 12 at 10:23 AM | seekingalpha.com

Mirum reports LIVMARLI Phase 3 trial success

October 12 at 9:00 AM | grafa.comG

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

October 12 at 9:00 AM | marketscreener.comM

Contrasting Mirum Pharmaceuticals (NASDAQ:MIRM) and Fate Therapeutics (NASDAQ:FATE)

October 12 at 7:44 AM | americanbankingnews.com

Mirum Pharmaceuticals to report Livmarli trial results Monday

October 11, 2026 | seekingalpha.com

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

October 11, 2026 | businesswire.com

Royal Bank Of Canada Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

October 10, 2026 | americanbankingnews.com

Mirum’s AZURE-2 Trial Pits Brelovitug Against Bulevirtide in High-Stakes Hepatitis D Study

October 8, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, EXEL, ASND, and HALO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$227.50 +0.50 (+0.22%)

As of 12:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$62.81 +1.82 (+2.98%)

As of 12:30 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Halozyme Therapeutics NASDAQ:HALO

$121.49 +4.67 (+4.00%)

As of 12:30 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$82.56 +2.60 (+3.25%)

As of 12:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRM, EXEL, ASND, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRM, EXEL, ASND, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRM, EXEL, ASND, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, EXEL, ASND, and HALO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRM, EXEL, ASND, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRM, EXEL, ASND, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRM, EXEL, ASND, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, EXEL, ASND, and HALO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools